切除修复交叉互补基因1(ERCC1),excision repair cross completion gene 1
excision repair cross-complementing 1(ERCC1)核苷酸切除修复交叉互补基因1(ERCC1)
3)ERCC1核苷酸切除修复交叉互补基因-1
1.Expression ofERCC1 in colorectal cancer and its clinical significance;核苷酸切除修复交叉互补基因-1在结直肠癌中的表达及其意义
4)excision repair cross-complementation group 1/ genetics切除修复交叉互补基因1/遗传学
5)ERCC1切除修复交叉互补基因1
1.Objective: To study the relation between expression of excision repair cross- complementing gene 1 (ERCC1) in tissue of non-small cell lung cancer and long-term effect of platinum-based chemotherapy.目的:研究探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中DNA切除修复交叉互补基因1(excision repair cross-complementing 1,ERCC1)的表达与铂类化疗远期疗效之间的关系,并观察该指标及相关临床因素对患者预后的影响。
2.A number of nucleic acid repair genes such as excision repair cross-complementing gene 1(ERCC1) and human xeroderma pigmentosum gene D(XPD/ERCC2),the level descent may be susceptible factors to one or certain kinds of tumors;but if these genes′ level are higher,the ability to repair damage and chemotherapy-induced genetic damage will be enhanced,it may be resistance to chemotherapeutic drugs.一些核酸修复基因,如切除修复交叉互补基因1(ERCC1)及人类着色性干皮病基因D(XPD/ERCC2)的水平下降,可能会成为某种或某几种肿瘤的易感因素;但如果此种基因的水平较高,修复损伤的能力提高,对化疗药物所致基因损伤的修复能力也就增强了,那么可能对化疗药物产生耐药现象。
6)Excision Repair Cross-Complementation group 1切除修复交叉互补基因1
1.Many factors affect the platinum-based chemotherapeutic effect including multidrug resistance gene 1(MDR1) andExcision Repair Cross-Complementation group 1.【目的】探讨多药耐药基因1和切除修复交叉互补基因1的多态性及其单体型对常用以铂类为基础两药联合方案治疗非小细胞肺癌的疗效、毒副作用等因素影响的规律,旨在为非小细胞肺癌化疗的个体化治疗提供新思路和新策略。
2.Objective To explore the correlation of the expression of excision repair cross-complementation group 1 (ERCC1) with non-small cell lung cancer (NSCLC) tissues and peripheral blood lymphocytes (PBLs).目的探讨切除修复交叉互补基因1(excision repair cross-complementation group 1,ERCC1)在人非小细胞肺癌(non-small cell lung cancer NSCLC)癌组织和外周血淋巴细胞(peripheral blood lymphocyte,PBL)中的表达及其相关性,以期建立临床实用简便的肿瘤学指标。
延伸阅读
切除1.用外科手术把身体上受伤或病变的部分切掉。
